A once-a-day oral tablet version of the weight-loss drug Wegovy is now available for private purchase at pharmacies across the United Kingdom [1, 2, 3].

The approval of the pill form represents a significant shift in accessibility for weight-loss medication. By moving away from the traditional injectable format, the drug becomes more convenient for patients and may reduce overall costs compared to the injectable version [1].

Novo Nordisk, the manufacturer of Wegovy, developed the tablet to provide a daily oral alternative [1, 2]. The medication has received official approval in the UK and transitioned to the private market as of Monday, July 6 [2, 3].

Public demand for the new format has been immediate. Reports indicate that 70,000 people in the UK are currently queueing to obtain the medication [4].

“A pill version of weight loss medicine Wegovy has been approved in the UK,” BBC News said [1]. This availability allows patients to bypass the needle-based administration required by previous iterations of the treatment.

“The once‑a‑day pill can now be bought privately in UK pharmacies,” MSN Health said [2]. The private sale model means that availability and pricing are handled through pharmacy providers rather than exclusively through national health services.

Because the drug is being sold privately, patients must coordinate with healthcare providers to secure the necessary prescriptions before purchasing the tablets at the pharmacy level [2, 3].

“The once‑a‑day pill can now be bought privately in UK pharmacies.”

The transition from an injectable to an oral tablet removes a primary psychological and physical barrier for patients seeking medical weight-loss intervention. By launching through private pharmacies, Novo Nordisk can capture immediate market demand and test the commercial viability of the oral format before potentially negotiating broader public health coverage.